1. Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients

   • Peter Ghijben
   • Dennis Petrie
   • Emily Lancsar

   Practical Application 09 April 2021 Pages: 741 - 756

   

2. Overview and Use of Tools for Selecting Modelling Techniques in Health Economic Studies

   • Huajie Jin
   • Stewart Robinson
   • Sarah Byford

   Review Article 20 May 2021 Pages: 757 - 770

   

3. Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine

   • Heleen Vellekoop
   • Simone Huygens
   • the HEcoPerMed Consortium

   Systematic Review Open access 16 April 2021 Pages: 771 - 788

   

4. Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review

   • Jalal Dahham
   • Rana Rizk
   • Mickaël Hiligsmann

   Systematic Review Open access 06 May 2021 Pages: 789 - 807

   

5. What are the Economic Costs to Society Attributable to Alcohol Use? A Systematic Review and Modelling Study

   • Jakob Manthey
   • Syed Ahmed Hassan
   • Jürgen Rehm

   Systematic Review Open access 10 May 2021 Pages: 809 - 822

   

6. Health Economists on Involving Patients in Modeling: Potential Benefits, Harms, and Variables of Interest

   • Stephanie Harvard
   • Gregory R. Werker

   Original Research Article Open access 07 May 2021 Pages: 823 - 833

   

7. Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group

   • Chantelle Murley
   • Petter Tinghög
   • Korinna Karampampa

   Original Research Article Open access 10 May 2021 Pages: 835 - 851

   

8. Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2− Advanced Breast Cancer: A Canadian Healthcare Perspective

   • Daniel Stellato
   • Marroon E. Thabane
   • Thomas E. Delea

   Original Research Article 18 May 2021 Pages: 853 - 867